Assessing adherence to oral chemotherapy using different measurement methods: Lessons learned from capecitabine

Persistence, adherence, and toxicity with oral CMF in older women with early-stage breast cancer (Adherence Companion Study 60104 for CALGB 49907)

(2012) K. J. Ruddy et al.   ANNALS OF ONCOLOGY

One vs Three Years of Adjuvant Imatinib for Operable Gastrointestinal Stromal Tumor

(2012) Heikki Joensuu et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Adherence with Oral Oncologic Treatment in Cancer Patients: Interest of an Adherence Score of All Dosing Errors

(2012) E. Thivat et al.   ONCOLOGY

The use of capecitabine in daily practice: a study on adherence and patients' experiences

(2012) Lonneke Timmers et al.   Patient Preference and Adherence

Capecitabine non-adherence: Exploration of magnitude, nature and contributing factors

(2012) Debi Bhattacharya et al.   JOURNAL OF ONCOLOGY PHARMACY PRACTICE

Poor adherence is the main reason for loss of CCyR and imatinib failure for chronic myeloid leukemia patients on long-term therapy

(2011) A. R. Ibrahim et al.   BLOOD

Self-Reported Compliance with Capecitabine: Findings from a Prospective Cohort Analysis

(2011) Ralph Winterhalder et al.   ONCOLOGY

Adherence and Persistence With Oral Adjuvant Chemotherapy in Older Women With Early-Stage Breast Cancer in CALGB 49907: Adherence Companion Study 60104

(2010) Ann H. Partridge et al.   JOURNAL OF CLINICAL ONCOLOGY

Adherence Is the Critical Factor for Achieving Molecular Responses in Patients With Chronic Myeloid Leukemia Who Achieve Complete Cytogenetic Responses on Imatinib

(2010) David Marin et al.   JOURNAL OF CLINICAL ONCOLOGY

Patient adherence and persistence with oral anticancer treatment

(2009) K. Ruddy et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial

(2009) Ronald P DeMatteo et al.   LANCET